C-SMART
Investigating a nasal spray option to prevent respiratory viral infections (eg COVID-19 and the Flu) in cancer patients.
RESULTS AVAILABLE SOON
Study has now closed
Studies have shown that people with cancer are more likely to develop severe respiratory infections such as COVID-19 and the flu and need admission more often to the ICU than people without cancer.
It is now recommended that immunosupressed people, such as those with cancer, receive a third booster shot of the COVID vaccine because they are particularly vulnerable to severe infection.
We have investigated if a low dose of the drug Interferon-alpha (delivered as a daily nasal spray) can also help to prevent COVID-19 and other viral respiratory infections in cancer patients.
Anyone with a past or current cancer diagnosis was eligible
RESULTS AVAILABLE SOON
Background and Rationale
Studies have shown that people diagnosed with cancer comprise about 10% of severe COVID-19 cases, and about 20% of those who die from it. They are also more likely to rapidly develop severe infections and need admission to the ICU compared to those without cancer.
Many clinical trials exclude cancer patients from their trial due to concerns about drug interactions and/or other unique health concerns.